| Drug Patent Number | Company | Drug Patent Title | Drug Patent Expiry | Activity Alert |
|---|---|---|---|---|
| These drug patents focus on the other aspects of the active substance like dosage, mode of administration (oral, tablet, capsules, liquids etc). | ||||
| US7049328 | CHIESI | Use for deferiprone |
Jun, 2021
(2 years ago) | |
| US8703156 | CHIESI | Liquid formulation for deferiprone with palatable taste |
Oct, 2029
(5 years from now) | |
| US10780055 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11357731 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11458103 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940116 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US10940115 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
| US11723874 | CHIESI | Delayed release deferiprone tablets and methods of using the same |
Oct, 2038
(14 years from now) | |
Ferriprox is owned by Chiesi.
Ferriprox contains Deferiprone.
Ferriprox has a total of 8 drug patents out of which 1 drug patent has expired.
Expired drug patents of Ferriprox are:
- US7049328
Ferriprox was authorised for market use on 14 October, 2011.
Ferriprox is available in tablet;oral, solution;oral dosage forms.
Ferriprox can be used as method of treating transfusional iron overload.
Drug patent challenges can be filed against Ferriprox from 15 October, 2015.
The generics of Ferriprox are possible to be released after 25 October, 2038.
| Drug Exclusivity | Drug Exclusivity Expiration |
|---|---|
| New Chemical Entity Exclusivity(NCE) | Oct 14, 2016 |
| Orphan Drug Exclusivity(ODE) | Oct 14, 2018 |
| New Indication(I-859) | Apr 30, 2024 |
| Orphan Drug Exclusivity(ODE-421) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-420) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-417) | Apr 30, 2028 |
| Orphan Drug Exclusivity(ODE-16) | Oct 14, 2018 |
Drugs and Companies using DEFERIPRONE ingredient
NCE-1 date: 15 October, 2015
Market Authorisation Date: 14 October, 2011
Treatment: Method of treating transfusional iron overload
Dosage: TABLET;ORAL; SOLUTION;ORAL
FERRIPROX family patents
